MetaVia to Showcase DA-1726 Obesity Data and Vanoglipel MASH Results on Feb. 25
MetaVia will present its DA-1726 obesity candidate and vanoglipel MASH therapy pipeline at the Emerging Growth Conference on February 25, 2026. DA-1726 delivered weight loss, glucose control and waist reduction in a Phase 1 trial, while vanoglipel reduced liver steatosis and improved glucose metabolism in a Phase 2a study.
1. Presenting at Emerging Growth Conference
MetaVia management will present a pipeline update on February 25, 2026 at 10:15 am ET at the Emerging Growth Conference. CEO Hyung Heon Kim and CFO Marshall Woodworth will detail progress on the DA-1726 obesity candidate and vanoglipel MASH therapy, followed by a Q&A session.
2. DA-1726 Phase 1 Trial Results
DA-1726 is an oxyntomodulin analogue acting as a dual GLP-1 and glucagon receptor agonist. In a Phase 1 multiple ascending dose trial, it achieved best-in-class weight loss, improved glucose control and reduced waist circumference in obese participants.
3. Vanoglipel Phase 2a Study Outcomes
Vanoglipel (DA-1241), a GPR119 agonist for Metabolic Dysfunction-Associated Steatohepatitis, demonstrated direct hepatic action in a Phase 2a study. It reduced steatosis, inflammation and fibrosis, while enhancing lipid metabolism and glycemic control.
4. Investor Registration and Q&A
Interested parties can register online to attend the virtual conference and submit questions in advance via email. One-on-one meetings with management can also be scheduled through the company’s investor relations contacts.